| Theme | Intestinal mucosal immunology update for clinician | |
|---|---|---|
| Title | Possibility and prospects for regulatory T cell-based cell therapy for inflammatory bowel disease | |
| Publish Date | 2011/09 | |
| Author | Kazuhiko Nakamura | Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University |
| [ Summary ] | CD4+ CD25+ regulatory T cells (Treg) have been shown to suppress animal models of inflammatory bowel disease (IBD) mediated by Th1, Th2 and Th17 types of inflammation. It is therefore expected that Treg-transfer therapy is efficacious for IBD treatment even though Th1, Th2 or Th17 reactions are involved in its pathogenesis. To realize the potential of Treg-therapy, methods for Treg isolation of a clinically applicable grade must be established. Using a clinical grade magnetic cell separation system, we established a Treg isolation system in which a large number of functionally preserved Treg could be isolated from leukapheresis products from IBD patients. Isolated Treg could be expanded in vitro with preserved functions. In addition, Treg could be induced from non-Treg in vitro. These results indicate that Treg-transfer therapy for IBD is feasible if its safety and efficacy are shown in clinical trials. | |